MiNK Therapeutics, Inc. SEC filings INKT
MiNK Therapeutics, Inc. has 265 filings in SEC EDGAR's recent list, going back to Jan 22, 2021. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 13, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Results of operations
|
May 15, 2026 | May 15, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 31, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Other events
|
Mar 27, 2026 | Mar 27, 2026 |
| 8-K |
Current report
Officer or director change
|
Mar 19, 2026 | Mar 13, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 2, 2026 | Dec 29, 2025 |
| 8-K |
Current report
Results of operations
|
Dec 8, 2025 | Nov 14, 2025 |
| 8-K |
Current report
Officer or director change
|
Sep 29, 2025 | Sep 23, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2025 | Aug 14, 2025 |
| 8-K |
Current report
Material agreement
|
Jul 15, 2025 | Jul 15, 2025 |
| 8-K |
Current report
Other events
|
Jul 14, 2025 | Jul 11, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2025 | Jun 18, 2025 |
| 8-K |
Current report
Results of operations
|
May 15, 2025 | May 15, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 18, 2025 | Mar 18, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jan 21, 2025 | Jan 17, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2024 | Nov 14, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 31, 2024 | Oct 30, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 18, 2024 | Oct 15, 2024 |
| 8-K |
Current report
Listing notice
|
Sep 13, 2024 | Sep 13, 2024 |
| 8-K |
Current report
Listing notice
|
Aug 30, 2024 | Aug 27, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2024 | Jun 12, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
May 16, 2024 | May 13, 2024 |
| 8-K |
Current report
Results of operations
|
May 14, 2024 | May 14, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 21, 2024 | Mar 21, 2024 |
| 8-K |
Current report
Listing notice
|
Feb 29, 2024 | Feb 23, 2024 |
| 8-K |
Current report
Material agreement, New debt
|
Feb 14, 2024 | Feb 12, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Officer or director change
|
Oct 17, 2023 | Oct 12, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 20, 2023 | Jun 13, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 21, 2023 | Mar 21, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2022 | Nov 3, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 9, 2022 | Aug 9, 2022 |
| 8-K |
Current report
Material agreement
|
Aug 5, 2022 | Aug 2, 2022 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 14, 2022 | Jun 8, 2022 |
| 8-K |
Current report
Results of operations
|
May 10, 2022 | May 10, 2022 |
| 8-K |
Current report
Officer or director change
|
Mar 8, 2022 | Mar 2, 2022 |
| 8-K |
Current report
Officer or director change
|
Jan 6, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Oct 20, 2021 | Oct 19, 2021 |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INKT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1840229
- Former names
- AgenTus Therapeutics, Inc. (until Mar 18, 2021); AgenTus Therapeutics, Inc. (until Mar 18, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.